A caffeic acid derivative and its preparation method and application
By developing a caffeic acid derivative, the problem of lack of effective NASH drugs in the prior art was solved, and by reducing ALT and AST levels and improving liver function, it provides new options for NASH treatment and broadens the range of existing compounds.
Patent Information
- Application Number
- CN202111172197.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-10-08
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2041-10-08
AI Technical Summary
There is no effective and safe drug for treating non-alcoholic steatohepatitis (NASH) in the prior art, and the disease pathogenesis and large heterogeneity of patients, resulting in huge challenges in the development of new NASH drugs.
A caffeic acid derivative is developed to prepare its pharmaceutically acceptable salt or pharmaceutical composition by specific synthetic methods for reducing the levels of alanine aminotransferase (ALT) and glutinotransferase (AST) to treat NASH. The structure of the compound includes the reaction of compound 1 and compound 2 in an organic solvent, the addition of a specific catalyst, and the purification of multiple steps gives a pharmacologically active compound.
The compounds can significantly reduce ALT and AST levels, improve liver function in mice, provide new anti-NASH compounds, broaden the range of existing compounds, and provide new options for the treatment of NASH.
Smart Images

Figure CN115960075B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to a caffeic acid derivative and a preparation method thereof and use thereof as a drug for treating non-alcoholic steatohepatitis (NASH). Background Art
[0002] Non-alcoholic fatty liver disease (NAFLD) is a metabolic stress liver disease closely related to insulin resistance and genetic susceptibility. The disease spectrum includes non-alcoholic hepatic steatosis, non-alcoholic steatohepatitis (NASH), NASH-related cirrhosis and hepatocellular carcinoma (HCC). The treatment goal of NASH is to delay, prevent, and reverse the progression of the disease and improve clinical outcomes, including reducing the occurrence of cirrhosis and its complications, reducing the need for liver transplantation, improving survival rates, and improving quality of life. However, current intervention measures, except for changing lifestyle (diet and exercise intervention, etc.) to achieve weight loss, can benefit some patients, but there are no clinical trials to confirm effective and safe drugs for the treatment of NASH. Even among NASH patients with liver fibrosis who undergo weight loss surgery, more than 50% of patients have no improvement or even worsening of liver fibrosis. Therefore, drug treatment for liver damage in NASH patients is crucial. Some key factors in the development of new NASH drugs are updated rapidly. Both my country and the U.S. Food and Drug Administration (FDA) have issued draft clinical research guidelines for NASH drug development. However, due to the complex pathogenesis of the disease and the large heterogeneity of patients, it faces many challenges. Although there are currently more than 50 therapeutic drugs in the clinical development stage, the success rate of clinical trials is low, the clinical treatment needs of patients in this field are not met, and there are still many key unresolved issues.
[0003] The pathogenesis of NASH has not yet been clearly defined. Previously, most scholars supported the theory that oxidative stress and lipid peroxidation, centered on the mitochondrial reactive oxygen species (ROS), further damage the liver, namely the "second hit" theory. In recent years, NASH drugs based on various new theories and new targets have entered clinical research, but their complex pathogenesis, disease heterogeneity, diagnostic barriers, and the choice of treatment endpoints have brought huge challenges to the development of new NASH drugs.
[0004] Intercept's Farnesoid X receptor (FXR) agonist obeticholic acid (OCA), the world's first drug to be submitted for marketing approval for the treatment of NASH, was rejected by the U.S. Food and Drug Administration (FDA) in June 2020 on the grounds that the expected benefits based on alternative histopathological trial endpoints were still uncertain and the benefits of treatment did not outweigh the potential risks (side effects of elevated LDL-C). In May 2020, GENFIT announced the failure of its peroxisome proliferator-activated receptor (PPAR) agonist GFT-505 (elafibranor) in Phase III clinical trials and stopped the development of the drug in the field of NASH. Gilead also announced the failure of its GS-4997 (selonsertib) in Phase III clinical trials.
[0005] Xu Guanglin et al. (CN102503932B) reported a class of gas signal molecule donors. By introducing hydrogen sulfide releasing groups into the compound structure, a series of compounds were synthesized, which have significant anti-inflammatory and / or anti-tumor activities. However, the patent document does not disclose and / or teach that the compounds can be used to treat non-alcoholic fatty liver disease.
[0006] S is
[0007] Elena Gabriele et al. (JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2017, 32(1), 1012-1028) disclose the use of caffeic acid derivatives as STAT3 and NF-kB inhibitors and can be used to treat cancer. However, the journal document also does not disclose and / or teach that the compounds can be used to treat non-alcoholic fatty liver disease.
[0008] From the above, we can see that the market prospects of NASH are huge, but the risks are also relatively high. Therefore, the development of new compounds that can be used to treat non-alcoholic fatty liver disease, especially anti-NASH drugs with independent intellectual property rights in my country, has important economic and social benefits. Summary of the invention
[0009] The technical problem to be solved by the present invention is to provide a caffeic acid derivative which can be used for treating non-alcoholic steatohepatitis (NASH).
[0010] The first aspect of the present invention is to provide a compound of formula I and a pharmaceutically acceptable salt thereof, which has the following structure:
[0011]
[0012] Wherein: X is selected from NH, S.
[0013] Preferably, the compound of formula I has the following structure:
[0014]
[0015] Preferably, the pharmaceutically acceptable salt is selected from: hydrochloride, hydrobromide, phosphate, sulfate, acetate, oxalate, tartrate, citrate, trifluoroacetate, methanesulfonate, ethanesulfonate, p-toluenesulfonate or salicylate;
[0016] Another aspect of the present invention provides a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier and excipient.
[0017] Preferably, the pharmaceutical composition is an oral preparation, an intravenous or intramuscular injection preparation, a topical administration preparation, or an inhalation preparation.
[0018] Preferably, the pharmaceutical composition is a tablet, capsule, sustained-release agent, controlled-release agent, injectable powder, injection, solution, suspension, emulsion, micropill, pill, powder, microemulsion, targeted preparation, or inhalant.
[0019] Another aspect of the present invention provides a method for preparing a compound of formula I, comprising the steps of:
[0020]
[0021] Compound 1 and compound 2 are dissolved in an organic solvent, and then 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and 4-dimethylaminopyridine are added, and the reaction is stirred at room temperature, and TLC is detected. After the reaction is completed, the solvent is dried under reduced pressure, water is added, and extracted three times with dichloromethane. After the organic layers are combined, they are dried over anhydrous sodium sulfate, filtered, and concentrated. The obtained residue is purified by silica gel column chromatography to obtain an intermediate;
[0022] The intermediate was added to anhydrous methanol containing sodium methoxide, stirred for reaction, and detected by TLC. After the reaction was completed, dichloromethane was added, and then washed twice with 1M dilute hydrochloric acid, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography to obtain the compound of formula I.
[0023] Another aspect of the present invention relates to the use of a compound of formula I and a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising the same in the preparation of a drug for treating non-alcoholic steatohepatitis, wherein the structure of the compound of formula I is as follows:
[0024]
[0025] Wherein: X is selected from O, S, and NH.
[0026] Preferably, the compound or the pharmaceutical composition comprising the compound can reduce alanine aminotransferase (ALT) and aspartate aminotransferase (AST).
[0027] definition:
[0028] In certain embodiments, the pharmaceutically acceptable form is a pharmaceutically acceptable salt, and pharmaceutically acceptable salts are well known in the art. Examples of pharmaceutically acceptable salts are forms of salts formed with compounds such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, perchloric acid, acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, lactic acid, trifluoroacetic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, etc.
[0029] "Pharmaceutically acceptable carriers" or "pharmaceutically acceptable excipients" include any and all solvents, dispersion media, coating agents, isotonic agents, absorption delaying agents, and the like. Pharmaceutically acceptable carriers or excipients do not destroy the pharmacological activity of the disclosed compounds and are non-toxic when administered in doses sufficient to deliver therapeutic amounts of the compounds. The use of such media and agents for pharmaceutically active substances is well known in the art.
[0030] Compared with the prior art, the present invention has the following beneficial effects:
[0031] (1) The present invention provides a new class of caffeic acid derivatives, which broadens the scope of existing anti-NASH compounds and can be used as lead compounds for further optimization;
[0032] (2) The compounds of the present invention can effectively reduce alanine aminotransferase (ALT) and aspartate aminotransferase (AST) and improve the liver function of mice. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] Figure 1 The changing trend of alanine aminotransferase (ALT) after administration of the compound CAS-1 of the present invention;
[0034] Figure 2 The changing trend of aspartate aminotransferase (AST) after administration of the compound CAS-1 of the present invention;
[0035] Figure 3 The changing trend of alanine aminotransferase (ALT) after administration of the compound CAS-2 of the present invention;
[0036] Figure 4 The changing trend of aspartate aminotransferase (AST) after administration of the compound CAS-2 of the present invention. DETAILED DESCRIPTION
[0037] The following examples are provided to illustrate the present invention in detail. The following examples are provided to better illustrate the present invention and are not intended to limit the scope of the present invention. The materials, reagents, etc. used in the following examples, unless otherwise specified, can be obtained from commercial sources.
[0038] Example 1 Synthesis of Compound CAS-1
[0039]
[0040] Dissolve diacetyl caffeic acid (compound 1, 2.64g) and compound 2 (2.26g) in chloroform (50ml), then add 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI, 3.8g) and 4-dimethylaminopyridine (DMAP, 122mg), stir at room temperature for 24 hours, detect by TLC, after the reaction, vacuum dry the solvent, add 50ml water, extract with 100ml dichloromethane three times, combine the organic layers, dry with anhydrous sodium sulfate, filter, concentrate, and purify the residue with silica gel column chromatography (dichloromethane: methanol = 10:1) to obtain 3.15g of the product. Add the above compounds to 50ml of anhydrous methanol containing 1.6g of sodium methoxide, stir for 24 hours, detect by TLC, after the reaction, add 50ml of dichloromethane, and then wash twice with 1M dilute hydrochloric acid, 20ml each time. The residue was dried over anhydrous sodium sulfate, filtered and concentrated, and purified by silica gel column chromatography (dichloromethane:methanol=10:1) to obtain 2.31 g of the product. 1 H NMR (400MHz, DMSO-d6) δ9.46(s,1H),9.43(s,1H),7.50(d,1H),6.67-7.30(m,7H),6.30(d,1H),5.65(s,1H). MS(ESI)m / z:388.99[M+H] + .
[0041] Example 2 Synthesis of Compound CAS-2
[0042]
[0043] Dissolve diacetyl caffeic acid (compound 1, 2.64g) and compound 3 (2.25g) in chloroform (50ml), then add 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI, 3.8g) and 4-dimethylaminopyridine (DMAP, 122mg), stir at room temperature for 24 hours, detect by TLC, after the reaction, decompress and spin dry the solvent, add 50ml water, extract with 100ml dichloromethane three times, combine the organic layers, dry with anhydrous sodium sulfate, filter, concentrate, and purify the residue with silica gel column chromatography (dichloromethane: methanol = 10:1) to obtain 3.07g of the product. Add the above compounds to 50ml of anhydrous methanol containing 1.6g of sodium methoxide, stir and react for 24 hours, detect by TLC, after the reaction, add 50ml of dichloromethane, and then wash twice with 1M dilute hydrochloric acid, 20ml each time. The residue was dried over anhydrous sodium sulfate, filtered and concentrated, and purified by silica gel column chromatography (dichloromethane:methanol=10:1) to obtain 2.12 g of the product. 1 H NMR (400MHz, DMSO-d6) δ9.49(s,1H),9.45(s,1H),9.24(s,1H),6.67-7.44(m,8H),6.33(d,1H),5.69(s,1H). MS(ESI)m / z:387.02[M+H] + .
[0044] Example 2 Inhibitory activity of the compounds of the present invention on alanine aminotransferase (ALT) and aspartate aminotransferase (AST)
[0045] C57BL / 6J male mice were randomly divided into groups. Except for the normal group (control group), the other animals were continuously fed with a high-fat diet for 10 weeks. After 10 weeks, CAS-1 or CAS-230.0 mg / kg (low-dose group), CAS-1 or CAS-260.0 mg / kg (high-dose group) or an equal volume of normal saline (normal control, model) were gavaged once a day. After 3 doses, the mice were fasted for 12 hours, and then blood was collected from the posterior orbital venous plexus of the mice, and the changes in serum ALT and AST levels were determined using a blood biochemical analyzer.
[0046] The results are as follows Figure 1-4As shown. Among them: control group represents normal mice; db / db represents the group that was continuously fed with high-fat diet for 10 weeks but not given any drug; db / db+CAS-1(low) represents the group that was continuously fed with high-fat diet for 10 weeks and was gavaged with CAS-1 or CAS-230.0 mg / kg, once a day; db / db+CAS-1(low) represents the group that was continuously fed with high-fat diet for 10 weeks and was gavaged with CAS-1 or CAS-260.0 mg / kg, once a day. Data are expressed as X±SEM (n=7-9). **P<0.01 indicates that db / m mice are compared with the model group; #P<0.05, ##P<0.01 indicates that db / db mice are compared with the control group. Multiple comparisons were analyzed by two-way ANOVA and Dunnett's test.
[0047] Depend on Figure 1-Figure 4 It can be seen that the compounds of the present invention can significantly reduce alanine aminotransferase ( Figure 1 , Figure 3 ) and aspartate aminotransferase ( Figure 2 , Figure 4 ) levels and improved the liver function of db / db mice, indicating that the compounds of the present invention have a certain therapeutic effect on NASH and can be used to prepare drugs for treating or preventing NASH, providing more options for its clinical treatment.
Claims
1. A compound of formula I or a pharmaceutically acceptable salt thereof, having the following structure: ; in: X is selected from NH, S.
2. The compound of formula I or a pharmaceutically acceptable salt thereof according to claim 1, wherein the structure is as follows: 。 3. A pharmaceutically acceptable salt of a compound of formula I according to claim 1 or 2, Features: The pharmaceutically acceptable salt is selected from the group consisting of hydrochloride, hydrobromide, phosphate, sulfate, acetate, oxalate, tartrate, citrate, trifluoroacetate, methanesulfonate, ethanesulfonate, p-toluenesulfonate or salicylate.
4. A method for preparing a compound of formula I as claimed in claim 1, comprising the following steps: ; Compound 1 and compound 2 are dissolved in an organic solvent, and then 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and 4-dimethylaminopyridine are added, and the reaction is stirred at room temperature, and TLC is detected. After the reaction is completed, the solvent is dried under reduced pressure, water is added, and extracted three times with dichloromethane. After the organic layers are combined, they are dried over anhydrous sodium sulfate, filtered, and concentrated. The obtained residue is purified by silica gel column chromatography to obtain an intermediate; The intermediate was added to anhydrous methanol containing sodium methoxide, stirred for reaction, and detected by TLC. After the reaction was completed, dichloromethane was added, and then washed twice with 1M dilute hydrochloric acid, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography to obtain the compound of formula I.
5. A pharmaceutical composition comprising the compound of formula I or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 3, and a pharmaceutically acceptable carrier.
6. The pharmaceutical composition according to claim 5, Features: The pharmaceutical composition is an oral preparation, an intravenous or intramuscular injection preparation, a local administration preparation, or an inhalation preparation.
7. The pharmaceutical composition according to claim 5, Features: The pharmaceutical composition is a tablet, a capsule, a sustained-release agent, an injection powder, an injection solution, a suspension, an emulsion, a pill, a powder, a targeted preparation, or an inhalant.
8. Use of a compound of formula I and a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising the same in the preparation of a method for treating non-alcoholic steatohepatitis, wherein the non-alcoholic steatohepatitis is caused by abnormal alanine aminotransferase (ALT) or aspartate aminotransferase (AST), wherein the structure of the compound of formula I is as follows: ; in: X is selected from O, S, and NH.
9. The use according to claim 8, Features: The structure of the compound of formula I is as follows: 。
